Compare · EW vs ZY
EW vs ZY
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Zymergen Inc. (ZY): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while ZY operates in Industrials - the two are in different parts of the market.
- EW is the larger of the two at $47.58B, about 97.4x ZY ($488.5M).
- EW has hit the wire 8 times in the past 4 weeks while ZY has been quiet.
- EW has more recent analyst coverage (25 ratings vs 13 for ZY).
- Company
- Edwards Lifesciences Corporation
- Zymergen Inc.
- Price
- $83.01+0.44%
- $2.44+2.10%
- Market cap
- $47.58B
- $488.5M
- 1M return
- -7.53%
- -
- 1Y return
- +5.79%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 13
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Zymergen Inc.
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.
Latest EW
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Latest ZY
- SEC Form 15-12G filed by Zymergen Inc.
- SEC Form EFFECT filed by Zymergen Inc.
- SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)
- SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares
- SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company
- SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company
- SEC Form 4: Peterson Sandra E returned 119,119 shares to the company, closing all direct ownership in the company
- SEC Form 4: Murdoch Travis returned 79,697 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gorjanc Christine Marie returned 50,000 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Sharma Rohit